In a large study reported in the New England journal of medicine, 147 out of 5547 patients (2.7%) with rectal cancers were MMR-deficient. Among a total of 16,065 colorectal adenocarcinomas, 2,150 (13.4%) were MMR-deficient.
Among patients with rectal cancer, those diagnosed younger than 50 years were more likely to have dMMR compared to those older than 50 years (4.2% versus 2.4%; P = .003).
.png)